Clinical Trials Logo

Clinical Trial Summary

Diffuse Macular Edema is the main cause of visual disorders in diabetic patients.

Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema.


Clinical Trial Description

Diffuse Macular Edema is the main cause of visual disorders in diabetic patients.

Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema. ;


Study Design

Intervention Model: Parallel Assignment, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00999791
Study type Interventional
Source hahid Beheshti University of Medical Sciences
Contact Masoud Soheilian, MD
Phone +982122585952
Email labbafi@hotmail.com
Status Recruiting
Phase Phase 1
Start date July 2009

See also
  Status Clinical Trial Phase
Terminated NCT00571142 - Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema Phase 3
Withdrawn NCT00567372 - POSTERIOR SUB-TENON'S Avastin Phase 4
Withdrawn NCT00600301 - Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study Phase 3
Completed NCT00886808 - Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema Phase 1
Recruiting NCT01218750 - Triple Therapy for Diffuse Diabetic Macular Edema N/A